Brokerages Set Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Target Price at $46.65

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has been given a consensus rating of “Moderate Buy” by the nineteen research firms that are presently covering the stock, MarketBeat.com reports. Eight analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $46.71.

A number of research firms have weighed in on APLS. HC Wainwright reissued a “buy” rating and set a $57.00 target price on shares of Apellis Pharmaceuticals in a research report on Tuesday, January 14th. Mizuho decreased their target price on Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a research note on Thursday, October 24th. Citigroup dropped their price target on Apellis Pharmaceuticals from $63.00 to $51.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Royal Bank of Canada reissued a “sector perform” rating and issued a $26.00 price objective on shares of Apellis Pharmaceuticals in a research report on Tuesday. Finally, Robert W. Baird dropped their target price on shares of Apellis Pharmaceuticals from $92.00 to $55.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th.

Apellis Pharmaceuticals Stock Performance

APLS opened at $30.13 on Wednesday. The stock has a 50-day moving average of $31.89 and a 200-day moving average of $33.31. The company has a debt-to-equity ratio of 1.91, a quick ratio of 3.73 and a current ratio of 4.36. Apellis Pharmaceuticals has a 52-week low of $24.34 and a 52-week high of $71.90. The company has a market cap of $3.75 billion, a PE ratio of -14.84 and a beta of 0.94.

Apellis Pharmaceuticals (NASDAQ:APLS) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The company had revenue of $196.83 million for the quarter, compared to analyst estimates of $200.00 million. During the same quarter last year, the business earned ($1.17) EPS. The company’s revenue for the quarter was up 78.3% on a year-over-year basis. As a group, equities research analysts forecast that Apellis Pharmaceuticals will post -1.71 earnings per share for the current fiscal year.

Insider Buying and Selling at Apellis Pharmaceuticals

In other Apellis Pharmaceuticals news, insider Caroline Baumal sold 2,816 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $33.81, for a total transaction of $95,208.96. Following the sale, the insider now directly owns 55,560 shares of the company’s stock, valued at approximately $1,878,483.60. This represents a 4.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Nur Nicholson sold 2,145 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Friday, January 17th. The shares were sold at an average price of $29.96, for a total transaction of $64,264.20. Following the completion of the transaction, the insider now owns 52,011 shares of the company’s stock, valued at $1,558,249.56. This trade represents a 3.96 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,106 shares of company stock worth $894,834 over the last three months. Company insiders own 6.80% of the company’s stock.

Institutional Trading of Apellis Pharmaceuticals

Several large investors have recently made changes to their positions in APLS. Merit Financial Group LLC acquired a new position in Apellis Pharmaceuticals during the 4th quarter worth about $254,000. Hennion & Walsh Asset Management Inc. raised its stake in shares of Apellis Pharmaceuticals by 135.6% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 29,740 shares of the company’s stock worth $949,000 after acquiring an additional 17,115 shares during the last quarter. Eastern Bank raised its stake in shares of Apellis Pharmaceuticals by 87.0% in the fourth quarter. Eastern Bank now owns 21,500 shares of the company’s stock worth $686,000 after acquiring an additional 10,000 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Apellis Pharmaceuticals by 23.3% during the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after purchasing an additional 735,160 shares in the last quarter. Finally, Exome Asset Management LLC grew its stake in shares of Apellis Pharmaceuticals by 114.0% during the third quarter. Exome Asset Management LLC now owns 100,367 shares of the company’s stock valued at $2,895,000 after purchasing an additional 53,467 shares during the last quarter. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).